Platelet-rich plasma enhances bone union in posterolateral lumbar fusion: A prospective randomized controlled trial

• Published in: The spine journal Vol. 19; no. 2; pp. e34 - e40
• Main Authors: Kubota, Go, Kamoda, Hiroto, Orita, Sumihisa, Yamauchi, Kazuyo, Sakuma, Yoshihiro, Oikawa, Yasuhiro, Inage, Kazuhide, Sainoh, Takeshi, Sato, Jun, Ito, Michihiro, Yamashita, Masaomi, Nakamura, Junichi, Suzuki, Takane, Takahashi, Kazuhisa, Ohtori, Seiji
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.02.2019
• Subjects: Adult; Aged; Bone Transplantation - adverse effects; Bone Transplantation - methods; Bone union; Female; Humans; Lumbar Vertebrae - surgery; Male; Middle Aged; Platelet-Rich Plasma; Posterolateral lumbar fusion; Postoperative Complications - epidemiology; Randomized; Spinal Fusion - adverse effects; Spinal Fusion - methods; Spine; Surgery; Transplantation, Homologous - adverse effects; Transplantation, Homologous - methods; Bone union; Posterolateral lumbar fusion; Randomized; Spine; Platelet-rich plasma; Surgery
• ISSN: 1529-9430; 1878-1632
• DOI: 10.1016/j.spinee.2017.07.167

Platelet-rich plasma (PRP) accelerates bone union in vivo in a rodent model of spinal fusion surgery. However, PRP's effect on bone union after spinal surgery remains unclear. The objective of this study was to evaluate the efficacy of PRP after posterolateral lumbar fusion (PLF) surgery. Single-center prospective randomized controlled clinical trial with 2-year follow-up. The patient sample included a total 62 patients (31 patients in the PRP group or 31 patients in the control group). The outcome measures included the bone fusion rate, the area of bone fusion mass, the duration of bone fusion, and the clinical score using the visual analog scale (VAS). We randomized 62 patients who underwent one- or two-level instrumented PLF for lumbar degenerative spondylosis with instability to either the PRP (31 patients) or the control (31 patients) groups. Platelet-rich plasma-treated patients underwent surgery using an autograft bone chip (local bone), and PRP was prepared from patient blood samples immediately before surgery; patients from the control group underwent PLF without PRP treatment. We assessed platelet counts and growth factor concentrations in PRP prepared immediately before surgery. The duration of bone union, the postoperative bone fusion rate, and the area of fusion mass were assessed using plain radiography every 3 months after surgery and by computed tomography at 12 or 24 months. The duration of bone fusion and the clinical scores for low back pain, leg pain, and leg numbness before and 3, 6, 12, and 24 months after surgery were evaluated using VAS. Data from 50 patients with complete data were included. The bone union rate at the final follow-up was significantly higher in the PRP group (94%) than in the control group (74%) (p=.002). The area of fusion mass was significantly higher in the PRP group (572 mm2) than in the control group (367 mm2) (p=.02). The mean period necessary for union was 7.8 months in the PRP group and 9.8 months in the control group (p=.013). In the PRP, the platelet count was 7.7 times higher and the growth factor concentrations were 50 times higher than those found in plasma (p<.05). There was no significant difference in low back pain, leg pain, and leg numbness in either group at any time evaluated (p>.05). Patients treated with PRP showed a higher fusion rate, greater fusion mass, and more rapid bone union after spinal fusion surgery than patients not treated with PRP.